THE IMPACT ON ACCESS TO INNOVATIVE DRUGS OF THE FIRST MANAGED ENTRY AGREEMENTS IN ROMANIA

被引：0
|
作者：
Chiriac, N. D. [1 ]
Radu, P. C. [1 ]
Pravat, M. A. [1 ]
机构：
[1] Roche Romania Srl, Bucharest, Romania
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.908
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP358
引用
收藏
页码：A503 / A503
页数：1
相关论文
共 50 条
  • [31] ASSESSMENT OF MANAGED ENTRY AGREEMENTS IN EUROPE AND THE US
    Fortier, K.
    Riodin, E. L.
    Nadkarni, S.
    VALUE IN HEALTH, 2017, 20 (05) : A65 - A65
  • [32] MANAGED ENTRY AGREEMENTS IN UK, ITALY AND SPAIN
    Tolley, C.
    Palazzolo, D.
    VALUE IN HEALTH, 2014, 17 (07) : A449 - A449
  • [33] A COMPARATIVE ANALYSIS ON APPLICATION OF MANAGED ENTRY AGREEMENTS (MEA) FOR ORPHAN DRUGS IN SELECTED EUROPEAN COUNTRIES
    Djambazov, S.
    Dacheva, A.
    Vutova, Y.
    Filipov, A.
    Vekov, T.
    VALUE IN HEALTH, 2020, 23 : S663 - S663
  • [34] MANAGED ACCESS AGREEMENTS UNDER THE CANCER DRUGS FUND (CDF): KEY METRICS AND DRIVERS
    Adler, B.
    Privolnev, Y.
    VALUE IN HEALTH, 2018, 21 : S61 - S61
  • [35] Integrative Review of Managed Entry Agreements: Chances and Limitations
    Carolina Zampirolli Dias
    Brian Godman
    Ludmila Peres Gargano
    Pâmela Santos Azevedo
    Marina Morgado Garcia
    Maurílio Souza Cazarim
    Laís Lessa Neiva Pantuzza
    Nelio Gomes Ribeiro-Junior
    André Luiz Pereira
    Marcus Carvalho Borin
    Isabella de Figueiredo Zuppo
    Roberto Iunes
    Tomas Pippo
    Renata Curi Hauegen
    Carlos Vassalo
    Tracey-Lea Laba
    Steven Simoens
    Sergio Márquez
    Carolina Gomez
    Luka Voncina
    Gisbert W. Selke
    Livio Garattini
    Hye-Young Kwon
    Jolanta Gulbinovic
    Aneta Lipinska
    Maciej Pomorski
    Lindsay McClure
    Jurij Fürst
    Rosana Gambogi
    Carla Hernandez Ortiz
    Vânia Cristina Canuto Santos
    Denizar Vianna Araújo
    Vânia Eloisa Araujo
    Francisco de Assis Acurcio
    Juliana Alvares-Teodoro
    Augusto Afonso Guerra-Junior
    PharmacoEconomics, 2020, 38 : 1165 - 1185
  • [36] Managed Entry Agreements: Tools of Necessity, Works in Progress
    Beninger, Paul
    CLINICAL THERAPEUTICS, 2025, 47 (02) : 115 - 116
  • [37] ADOPTION OF MANAGED ENTRY AGREEMENTS IN ESTABLISHED AND EMERGING MARKETS
    Xue, Y.
    Montilva, J.
    Degun, R.
    VALUE IN HEALTH, 2016, 19 (07) : A835 - A836
  • [38] Integrative Review of Managed Entry Agreements: Chances and Limitations
    Dias, Carolina Zampirolli
    Godman, Brian
    Gargano, Ludmila Peres
    Azevedo, Pamela Santos
    Garcia, Marina Morgado
    Cazarim, Maurilio Souza
    Neiva Pantuzza, Lais Lessa
    Ribeiro-Junior, Nelio Gomes
    Pereira, Andre Luiz
    Borin, Marcus Carvalho
    Zuppo, Isabella de Figueiredo
    Iunes, Roberto
    Pippo, Tomas
    Hauegen, Renata Curi
    Vassalo, Carlos
    Laba, Tracey-Lea
    Simoens, Steven
    Marquez, Sergio
    Gomez, Carolina
    Voncina, Luka
    Selke, Gisbert W.
    Garattini, Livio
    Kwon, Hye-Young
    Gulbinovic, Jolanta
    Lipinska, Aneta
    Pomorski, Maciej
    McClure, Lindsay
    Furst, Jurij
    Gambogi, Rosana
    Ortiz, Carla Hernandez
    Canuto Santos, Vania Cristina
    Araujo, Denizar Vianna
    Araujo, Vania Eloisa
    Acurcio, Francisco de Assis
    Alvares-Teodoro, Juliana
    Guerra-Junior, Augusto Afonso
    PHARMACOECONOMICS, 2020, 38 (11) : 1165 - 1185
  • [39] Financial Outcomes of Managed Entry Agreements for Pharmaceuticals in Italy
    Trotta, Francesco
    Guerrizio, Maria Alessandra
    Di Filippo, Aurora
    Cangini, Agnese
    JAMA HEALTH FORUM, 2023, 4 (12): : E234611
  • [40] MANAGED-ENTRY AGREEMENTS: POSSIBLE OPTIONS FOR VACCINES?
    Baron-Papillon, F.
    Easley, C.
    Saint Sardos, C.
    Lucas, F.
    VALUE IN HEALTH, 2014, 17 (07) : A686 - A686
12345